Abstracts Archive - Page 2369 of 2425 - ACR Meeting Abstracts

Abstract Number: 812 • 2012 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
Michael Weinblatt¹, Clifton O. Bingham III², Alan Mendelsohn³, Lenore Noonan⁴, Shihong Sheng⁵, Lilianne Kim⁶, Kim Hung⁶, Jiandong Lu⁶, Daniel Baker⁶ and Rene Westhovens⁷, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Department of Medicine, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁴Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁵Biostatistics, Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase…
Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S. Smolen¹, D. Aletaha², D. Gruben³, J. D. Bradley⁴, S. H. Zwillich³, S. Krishnaswami³, B. Benda⁵ and C. Mebus⁶, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Pfizer Inc., Groton, CT, ⁴Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁵Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Arthur G. Pratt¹, Philip M. Brown², Simon J. Cockell³, Gillian Wilson⁴ and John D. Isaacs¹, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Directorate of Musculoskeletal Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…
Abstract Number: 775 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Roy Fleischmann¹, Ronald F. van Vollenhoven², Josef S. Smolen³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Hartmut Kupper⁷ and Arthur Kavanaugh⁸, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Karolinska Institute, Stockholm, Sweden, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁸UCSD School of Medicine, La Jolla, CA
Background/Purpose: In rheumatoid arthritis (RA), anti-TNF therapy is considered following 3-6 months of failed methotrexate (MTX) treatment. Some patients (pts), particularly those with many risk…
Abstract Number: 776 • 2012 ACR/ARHP Annual Meeting
A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission
Katerina Chatzidionysiou¹, Carl Turesson², Annika Teleman³, Ann Knight⁴, Elisabet Lindqvist⁵, Per Larsson⁶, Lars Cöster⁷, Barbro Rydberg⁸, Ronald F. van Vollenhoven⁹ and Mikael Heimbürger¹⁰, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁴Dept of Rheumatology, Institution for Medical Sciences, Uppsala University, Uppsala, Sweden, ⁵Department of Clinical Sciences, Section for Rheumatology Lund University, Lund, Sweden, ⁶Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Rheumatology, University Hospital, Linköping, Sweden, ⁸Department of Rheumatology, Kärnsjukhuset, Skövde, Sweden, ⁹Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ¹⁰Medical department, Abbott Scandinavia, Stockholm, Sweden
Background/Purpose: Treatment with TNF blockers, once started as therapy for RA, is usually continued indefinitely. Information about the possibility to discontinue anti-TNF therapy in RA…
Abstract Number: 777 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study
Robert B. M. Landewé¹, Martin Rudwaleit², Désirée van der Heijde³, Maxime Dougados⁴, Walter P. Maksymowych⁵, Jürgen Braun⁶, Atul A. Deodhar⁷, Christian Stach⁸, Bengt Hoepken⁸, Geoffroy Coteur⁹, Danuta Kielar⁹, Andreas Fichtner⁸, Terri Arledge¹⁰ and Joachim Sieper¹¹, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Endokrinologikum Berlin, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Oregon Health & Science University, Portland, OR, ⁸UCB Pharma, Monheim am Rheim, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Rtp, NC, ¹¹Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Axial spondyloarthritis (axSpA ) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), as defined by the ASAS criteria.1 RAPID-axSpA (NCT01087762) is the first…
Abstract Number: 778 • 2012 ACR/ARHP Annual Meeting
Spinal MRI Has Little Incremental Diagnostic Value Compared with MRI of the Sacroiliac Joints Alone in Early Spondyloarthritis
Ulrich Weber¹, Veronika Zubler², Zheng Zhao³, Robert GW Lambert⁴, Stanley Chan⁵, Susanne Juhl Pedersen⁶, Mikkel Ostergaard⁷ and Walter P. Maksymowych⁸, ¹Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ²Radiology, Balgrist University Hospital, Zurich, Switzerland, ³Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁴Radiology, University of Alberta, Edmonton, AB, Canada, ⁵Division of Ophthalmology, University of Alberta, Edmonton, AB, Canada, ⁶Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁷Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The definition of a positive MRI as major criterion in the Assessment of SpondyloArthritis classification criteria for axial spondyloarthritis (SpA) is based on MRI…
Abstract Number: 779 • 2012 ACR/ARHP Annual Meeting
Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁹ and Nathan Vastesaeger¹⁰, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp & Dohme, Kenilworth, NJ, ⁹Merck Sharp and Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Few studies have evaluated changes in active inflammation of spine and sacroiliac (SI) joints by MRI during long-term treatment for axial SpA, and no…
Abstract Number: 780 • 2012 ACR/ARHP Annual Meeting
The Relationship of Inflammation, Fatty Degeneration and the Effect of Long-Term TNF-Blocker Treatment On the Development of New Bone Formation in Patients with Ankylosing Spondylitis
Xenofon Baraliakos¹, Frank Heldmann², Joachim Listing³, Johanna Callhoff³, Jürgen Braun² and EASIC⁴, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Herne, Germany
Background/Purpose: Clinical trial results suggest that new bone formation is neither inhibited nor augmented by anti-TNF agents in ankylosing spondylitis (AS). Recently, a potential role…
Abstract Number: 781 • 2012 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Is Associated with an Increased Risk of Osteoporotic Fractures: A Population-Based Cohort Study
Juan Muñoz-Ortego¹, Peter Vestergaard², Josep Blanch³, Paul Wordsworth⁴, Andrew Judge⁵, M. Kassim Javaid⁶, Nigel K. Arden⁷, Cyrus Cooper⁸, Adolfo Díez-Pérez⁹ and Daniel Prieto-Alhambra¹⁰, ¹Rheumatology, Hospital Sagrat Cor, Barcelona (Spain), Barcelona, Spain, ²Endocrinology and Internal Medicine (MEA), Aarhus University Hospital THG, Aarhus (Denmark), Aarhus, Denmark, ³Rheumatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain, ⁴Ndorms, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ⁵Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Rheumatology, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁷NDORMS; MRC Lifecourse Epidemiology Unit, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁸NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom, ⁹Internal Medicine, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, ¹⁰Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain
TITLE: "Ankylosing Spondylitis is associated with an increased risk of osteoporotic fractures: a population-based cohort study."Background/Purpose: Patients with Ankylosing Spondylitis (AS) have reduced bone mass,…
Abstract Number: 782 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis
Nigil Haroon¹, Robert D. Inman², Thomas J. Learch³, Michael H. Weisman⁴, Michael M. Ward⁵, John D. Reveille⁶ and Lianne S. Gensler⁷, ¹Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Cedars-Sinai, Los Angeles, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁶Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The influence of anti-TNF therapy on radiographic progression in ankylosing spondylitis (AS) is not well established. We studied this effect on radiographic progression in…
Abstract Number: 783 • 2012 ACR/ARHP Annual Meeting
The Wnt Inhibitors DKK1 and SFRP1 Are Downregulated by Promoter Hypermethylation in Systemic Sclerosis
Clara Dees¹, Inga Schlottmann¹, Robin Funke¹, Alfiya Distler², Katrin Palumbo-Zerr², Pawel Zerr², Oliver Distler³, Georg A. Schett⁴ and Joerg HW Distler², ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Tissue fibrosis caused by pathological activation of fibroblasts is a major hallmark of systemic sclerosis (SSc). Epigenetic gene silencing of anti-fibrotic genes such as…
Abstract Number: 784 • 2012 ACR/ARHP Annual Meeting
Neutralization of Plasminogen Activator Inhibitor-1 Resolves Skin Fibrosis and Vascular Injury in a Murine Model of Human Scleroderma
Raphael Lemaire¹, Tim Burwell¹, Tracy Delaney¹, Cindy Chen², Julie Bakken¹, Lily Cheng¹, Philip Brohawn¹, Isabelle de Mendez³, Dominic Corkill³, Anthony Coyle⁴, Ronald Herbst² and Jane Connor¹, ¹Research, MedImmune LLC, Gaithersburg, MD, ²Respiration, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, ³Research, Medimmune, LLC, Cambridge, England, ⁴Centers for Therapeutic Innovation, Pfizer, Inc., Cambridge (formerly at MedImmune LLC, Gaithersburg, MD, USA), MA
Background/Purpose: Scleroderma is a systemic autoimmune disease in which thrombosis and fibrosis contribute to skin pathology. Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of…
Abstract Number: 785 • 2012 ACR/ARHP Annual Meeting
Resident Lung Fibroblast Gene Expression Signatures Predict Susceptibility or Resistance to Experimental Lung Fibrosis
Emma Derrett-Smith¹, Rachel Hoyles¹, Korsa Khan², David J. Abraham³ and Christopher P. Denton², ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ³UCL Medical School, London, United Kingdom
Background/Purpose: In scleroderma (SSc), lung fibrosis is linked to epithelial damage and dysregulated repair mechanisms. Resident lung fibroblasts may affect multiple cell types including…
Abstract Number: 786 • 2012 ACR/ARHP Annual Meeting
Crosstalk Between Integrins and TGFβ in the Pathogenesis and Treatment of Multiple Presentations of Scleroderma
Elizabeth E. Gerber¹, Fredrick M. Wigley², Elaine C. Davis³, David L. Huso⁴ and Harry C. Dietz¹, ¹Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada, ⁴Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma, defined as pathologic fibrosis of the skin, has many clinical presentations. In the most commonly recognized form, systemic sclerosis (SSc), previously healthy individuals…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].